Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 5, 2010, Pages 639-650

  Hopkins, Alyse ^a   Crowe, Philip J ^b   Yang, Jia Lin ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chemoresistance; Chemotherapy; Combination cancer therapy; IGF 1R targeted therapy

Indexed keywords

AMG 479; ASPARAGINASE; AVE 1642; CARBOPLATIN; CISPLATIN; CP 751871; CYTARABINE; DACTINOMYCIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; IFOSFAMIDE; IMC A 12; INSM 18; MERCAPTOPURINE; METHOTREXATE; MK 0646; NVP AEW 541; PACLITAXEL; PANITUMUMAB; PENTOSTATIN; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ANEMIA; ANOREXIA; ARTHRALGIA; BACKACHE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHILL; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EWING SARCOMA; FATIGUE; FECES; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; INJECTION SITE REACTION; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MEDLINE; MULTIPLE MYELOMA; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PANCREAS CANCER; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PRURITUS; PSORIASIS; RASH; REVIEW; SARCOMA; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 77950502920     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0792-0     Document Type: Review

References (83)

1. Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E (2008) Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 20:731-735
2. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Therapeutics 315:971-979
3. Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H et al (2008) A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor- 1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. ASCO Meet Abstr 26:3519
4. Bohula EA, Playford MP, Macaulay VM (2003) Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 14:669-682
5. Burfeind P, Chernicky C, Rininsland F, Ilan J, Ilan J (1996) Antisense RNA to the type 1 insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93:7263-7268
6. Busund L, Ow K, Russell P, Crowe PJ, Yang J (2004) Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: signiWcant correlation with malignant potential. Virchows Arch 444:142-148
7. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor 1 receptor. Cancer Res 65:3781-3787
8. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X (2008) The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 13:3273-3287
9. Chernicky C, Yi L, Tan H, Gan S, Ilan J (2000) Treatment of human breast cancer cells with antisense RNA to the type 1 insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7:385-395
10. Clark MA, Fisher C, Judson IM, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701-711
11. Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A (2007) Ionising radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26:2423-2434
12. Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD et al (2005) Delayed activation of the insulin-like growth factor-1 receptro/ Src/MAPL/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280:14212-14221
13. Djavan B, Waldert M, Seitz C, Marberger M (2001) Insulin-like growth factors and prostate cancer. World J Urol 19:225-233
14. Druckman R, Rohr U (2002) IGF-1 in gynaecology and obstetrics. Maturitas 41:S65-S83
15. Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager M, Larsson O (2002) Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Opthalmol Vis Sci 43:1-8
16. Featherstone C, Jackson SP (1999) Ku, a DNA repair protein with multiple cellular functions? Mutat Res 434:3-15
17. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL et al (2007) American Cancer Society, Atlanta, GA
18. Ge J, Chen Z, Wu S, Chen J, Li X, Li J et al (2009) Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148-158
19. Gil-Ad I, Shtaif B, Luria D, Karp L, Fridman Y, Weizman A (1999) Insulin like growth factor 1 (IGF-1R) antagonises apoptosis induced by serum deWciency and doxorubicin in neuronal cell culture. Growth Horm IGF Res 9:458-464
20. Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109S-3120S
21. Girnita L, Girnita A, Prete F, Bartolazzi A, Larrson O, Axelson M (2004) Cyclolignans as inhibitors of the insulin-like growth factor- 1 receptor and malignant cell growth. Cancer Res 64:236-242
22. Gooch JL, Van Den Berg CL, Yee D (1999) Insulin-like growth factor 1 (IGF-1) rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56:1-10
23. Hakam A, Yeatman T, Lu L, Mora L, Marcet G, Nicosia S et al (1999) Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30:1128-1133
24. Haluska P, Shaw H, Batzel GN, Molife LR, Adjei AA, Yap TA et al (2007) Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. ASCO Meet Abstr 25:3586
25. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207
26. Hartog H, Wesseling J, Boezen HM, van der Graaf WT (2007) The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43:1895-1904
27. Harzstark AL, Ryan C, Diamond M, Jones J, Zavodovskaya M, Maddux B et al (2007) A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J Clin Oncol 25:15500
28. Hewish M, Chau I, Cunningham D (2009) Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4:54-72
29. Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL et al (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. ASCO Meet Abstr 26:3520
30. Higano CS, Yu EY, Whiting SH, Gordon MS, LoRusso P, Fox F et al (2007) A phase I, Wrst in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. ASCO Meet Abstr 25:3505
31. Hochberg Z (2002) Mechanisms of steroid impairment of growth. Horm Res 58:33-38
32. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM et al (2009) The mechanisms of diVerential sensitivity to an insulinlike growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161-170
33. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics. CA Cancer J Clin 56:106-130
34. Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM (1999) Induction of tumor suppression and glandular diVerentiation of A549 lung carcinoma cells by dominant-negative IGF-1 receptor. Oncogene 18:6071-6077
35. Karp DD, Paz-Ares LG, Blakely LJ, Kreisman H, Eisenberg PD, Cohen RB et al (2007) Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as Wrst-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meet Abstr 25:7506
36. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al (2009) Phase II study of the efficacy of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. J Clin Oncol 27:2516-2522
37. Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A (2007) Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 62:9-15
38. Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7:25-41
39. Kuhn C, Hurwitz SA, Kumar MG, Cotton J, Spandau DF (1999) Activation of the insulin like growth factor-1 receptor promotes the survival o human keratinocytes following ultraviolet B irradiation. Int J Cancer 80:431-438
40. Lacy M, Alsina M, Melvin CL, Roberts L, Yin D, Petersen A et al (2006) Phase 1 Wrst-in-human dose escalation study of cp-751,871, a speciWc monoclonal antibody against the insulin like growth factor 1 receptor. J Clin Oncol 24:7609
41. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 Receptor monoclonal antibody CP-751, 871 in patients with multiple myeloma. J Clin Oncol 26:3196-3203
42. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L et al (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68:7966-7974
43. Larrson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 92:2097-2101
44. Lee C, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik I et al (1996) Antitumor eVects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56:3038-3041
45. Lee JY, Han CY, Yang JW, Smith C, Kim SK, Lee EY et al (2007) Induction of glutathione transferase in insulin-like growth factor 1 receptor- overexpressed hepatoma cells. Mol Pharmacol 72:1082-1093
46. Liu X, Turbyville T, Fritz A, Whitesell L (1998a) Inhibition of insulinlike growth factor 1 receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 58:5432-5438
47. Liu Y, Lehar S, Corvi C, Payne G, O'Connor R (1998b) Expression of the insulin like growth factor 1 receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res 58:570-576
48. Lloret M, Lara PC, Bordon E, Pinar B, Rev A, Falcon O et al (2007) IGF-1R expression in localised cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 106:8-11
49. Lopez T, Hanahan D (2002) Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1:339-353
50. Macaulay VM (2004) The IGF receptor as anticancer treatment target. Novartis Found Symp 262:235-243 (discussion 243-246)
51. Maloney E, McLaughlin J, Dagdigian N, Garrett L, Connors K, Zhou XH et al (2003) An anti-insulin-like growth factor 1 receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073-5083
52. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E et al (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444:1038-1043
53. Peters JM, Tsark EC, Wiley LM (1996) Radiosensitive target in the mouse embryo chimera assay: implications that the target involves autocrine growth factor function. Radiat Res 175:722-729
54. Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224-1228 (Pubitemid 30407009)
55. ResnicoV M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R (1994a) Growth inhibition of human melanoma cells in nude mice by antisense strategies to type 1 insulin-like growth factor receptor. Cancer Res 54:4848-4850
56. ResnicoV M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R et al (1994b) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1R) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218-2222
57. Riedemann J, Sohail M, Macaulay VM, Riedemann J, Sohail M, Macaulay VM (2007) Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochem Biophys Res Commun 355:700-706
58. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM, Rochester MA et al (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wildtype and mutant human prostate cancer. Cancer Gene Ther 12:90-100
59. Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias C (2007) A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. ASCO Meet Abstr 25:3590
60. Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8:197-209
61. Salisbury AJ, Macaulay VM (2003) Development of molecular agents for IGF receptor targeting. Horm Metab Res 35:843-849
62. Samani A, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20-47
63. Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F et al (2008) A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). ASCO Meet Abstr 26:3583
64. Scharf J, Dombrowski F, Ramadori G (2001) The IGF axis and hepatocarcinogenesis. J Clin Pathol 54:138-144
65. Scotlandi K (2006) Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 587:13-22
66. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S et al (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65:3868-3876
67. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic Wbroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90:11217-11221
68. Surmacz E (2000) Function of the IGF-1 Receptor in breast cancer. J Mammary Gland Biol Neoplasia 5:95-105
69. Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor 1 receptor. Oncogene 22:6589-6597
70. Tanaka S, Arii S (2009) Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100:1-8
71. Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L et al (2007) A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. ASCO Meet Abstr 25:3002
72. Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients (pts) with advanced solid tumor. ASCO Meet Abstr 26:3582
73. Traxler P (2003) Tyrosine kinases as targets in cancer therapy-successes and failures. Oncol Res 7:215-234
74. Turner B, Haffty B, Narayanan L, Yuan J, Havre P, Gumbs A et al (1997) Insulin-like growth factor-1 receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079-3083
75. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O (2004) The cyclolignan PPP induces activation loop-speciWc inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23:7854-7862
76. Von Mehren M (2003) New therapeutic strategies for soft tissue sarcomas. Curr Opin Oncol 4:441-451
77. Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Proc Natl Acad Sci USA 93:8318-8323
78. Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials- early lessons. J Mammary Gland Biol Neoplasia 13:471-483
79. Wunder J, Nielsen T, Maki R, O'Sullivan B, Alman B (2007) Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8:513-524
80. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O (1999) Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59:3588-3591
81. Yakar S, LeRoith D, Brodt P (2005) The role of the growth hormone/ insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407-420
82. Yang JL, Crowe PJ (2007) Targeted therapies in adult soft tissue sarcomas. J Surg Oncol 95:183-184
83. Zaidi SH, Huddart RA, Harrington KJ (2009) Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 6:103-134